Dual sugar blood testing to identify liver cirrhosis patients with leaky bowel wall and antibiotic use to prevent fatal intra-abdominal bacterial infections.
Phase 4
- Conditions
- Spontaneous bacterial peritonitisLiver cirrhosis
- Registration Number
- ACTRN12618001039279
- Lead Sponsor
- Gastroenterology Department, The Queen Elizabeth hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
How does dual sugar testing detect gut permeability in cirrhosis patients for SBP prediction in ACTRN12618001039279?
What molecular pathways link increased intestinal permeability to spontaneous bacterial peritonitis in liver cirrhosis?
Are there biomarkers beyond gut permeability that predict SBP risk in cirrhosis patients with bacterial translocation?
What are the long-term adverse effects of antibiotic prophylaxis in cirrhosis patients with leaky gut syndrome?
How does dual sugar testing compare to lactulose/mannitol assays in identifying gut barrier dysfunction in cirrhosis?